AU2016219906B2 - Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof - Google Patents

Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof Download PDF

Info

Publication number
AU2016219906B2
AU2016219906B2 AU2016219906A AU2016219906A AU2016219906B2 AU 2016219906 B2 AU2016219906 B2 AU 2016219906B2 AU 2016219906 A AU2016219906 A AU 2016219906A AU 2016219906 A AU2016219906 A AU 2016219906A AU 2016219906 B2 AU2016219906 B2 AU 2016219906B2
Authority
AU
Australia
Prior art keywords
fold
compound
cooh
compound according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016219906A
Other languages
English (en)
Other versions
AU2016219906A1 (en
Inventor
Ben C. Askew
Takeru Furuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scifluor Life Sciences Inc
Original Assignee
Scifluor Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scifluor Life Sciences Inc filed Critical Scifluor Life Sciences Inc
Publication of AU2016219906A1 publication Critical patent/AU2016219906A1/en
Application granted granted Critical
Publication of AU2016219906B2 publication Critical patent/AU2016219906B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016219906A 2015-02-19 2016-02-19 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof Ceased AU2016219906B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118303P 2015-02-19 2015-02-19
US62/118,303 2015-02-19
PCT/US2016/018612 WO2016134223A2 (en) 2015-02-19 2016-02-19 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2016219906A1 AU2016219906A1 (en) 2017-09-07
AU2016219906B2 true AU2016219906B2 (en) 2020-10-01

Family

ID=56689184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016219906A Ceased AU2016219906B2 (en) 2015-02-19 2016-02-19 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

Country Status (13)

Country Link
US (5) US9790222B2 (OSRAM)
EP (2) EP3925959A1 (OSRAM)
JP (2) JP2018510139A (OSRAM)
KR (1) KR102647026B1 (OSRAM)
CN (2) CN107531699A (OSRAM)
AU (1) AU2016219906B2 (OSRAM)
BR (1) BR112017017888A2 (OSRAM)
CA (1) CA2976634C (OSRAM)
ES (1) ES2892954T3 (OSRAM)
IL (1) IL253873A0 (OSRAM)
RU (1) RU2017132433A (OSRAM)
TW (1) TWI736529B (OSRAM)
WO (1) WO2016134223A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
ES2763556T3 (es) 2013-02-07 2020-05-29 Scifluor Life Sciences Inc Antagonistas fluorados de integrina
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) * 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
US20180110762A1 (en) * 2015-03-26 2018-04-26 Merck Sharp & Dohme Corp Compositions Methods for Treating Chronic Kidney Disease
KR20170141757A (ko) * 2015-04-30 2017-12-26 사이플루어 라이프 사이언시즈, 인크 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
LT3538528T (lt) 2016-11-08 2021-03-10 Bristol-Myers Squibb Company Pirolo amidai, kaip alfa v integrino inhibitoriai
JP7128811B2 (ja) 2016-11-08 2022-08-31 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
CA3042707A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
US10253025B2 (en) * 2017-03-30 2019-04-09 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
BR112020008893A2 (pt) 2017-11-07 2020-10-13 Bristol-Myers Squibb Company derivados de pirrolopirazina como inibidores de alfa v integrina
EP3784269B1 (en) * 2018-04-27 2024-06-05 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof
TWI857918B (zh) * 2018-08-29 2024-10-01 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
MX2022013753A (es) * 2020-05-07 2023-01-30 Pliant Therapeutics Inc Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
WO2021231581A1 (en) 2020-05-12 2021-11-18 Scifluor Life Sciences, Inc. METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS
CN116390754A (zh) * 2020-10-20 2023-07-04 莱兰斯坦福初级大学评议会 用于过继细胞治疗的可注射水凝胶

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410526B1 (en) * 1999-06-02 2002-06-25 Merck & Co., Inc. αv integrin receptor antagonists
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007700A1 (fr) 1987-03-30 1988-10-06 Anritsu Corporation Generateur de signaux lumineux et systeme d'etalonnage d'un appareil de mesure de la puissance lumineuse utilisant ledit generateur
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
ES2104938T3 (es) 1991-04-01 1997-10-16 Univ Duke Metodo de inhibir la fibrosis.
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
ATE294163T1 (de) 1997-12-17 2005-05-15 Merck & Co Inc Integrin-rezeptor-antagonisten
JP3589633B2 (ja) 1997-12-17 2004-11-17 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
US6455539B2 (en) * 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AU780364B2 (en) 2000-01-20 2005-03-17 Merck Sharp & Dohme Corp. Alpha V integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
AU2001277935B2 (en) 2000-07-26 2005-08-04 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
JP2004509123A (ja) 2000-09-14 2004-03-25 メルク　エンド　カムパニー　インコーポレーテッド アルファνインテグリン受容体アンタゴニスト
AU2001295038A1 (en) * 2000-09-18 2002-03-26 Merck & Co., Inc. Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
US7074930B2 (en) 2001-11-06 2006-07-11 Merck & Co., Inc Amine salts of an integrin receptor antagonist
US20040053968A1 (en) 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
AU2003267216A1 (en) 2002-09-20 2004-04-08 Merck & Co., Inc. Mannitol formulation for integrin receptor antagonist
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US20070117849A1 (en) * 2003-10-01 2007-05-24 Simon Goodman Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents
CA2715034C (en) * 2008-03-14 2016-12-06 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
NZ705135A (en) 2010-05-26 2017-10-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
CN104080467B (zh) 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
KR20170141757A (ko) 2015-04-30 2017-12-26 사이플루어 라이프 사이언시즈, 인크 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
US10253025B2 (en) * 2017-03-30 2019-04-09 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410526B1 (en) * 1999-06-02 2002-06-25 Merck & Co., Inc. αv integrin receptor antagonists
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Registry No. 227963-76-0 (Entered STN Jul. 16, 1999). *

Also Published As

Publication number Publication date
JP7191299B2 (ja) 2022-12-19
US11685738B2 (en) 2023-06-27
CN107531699A (zh) 2018-01-02
BR112017017888A2 (pt) 2018-04-10
AU2016219906A1 (en) 2017-09-07
EP3259271B1 (en) 2021-05-05
WO2016134223A2 (en) 2016-08-25
US20210277000A1 (en) 2021-09-09
US9790222B2 (en) 2017-10-17
CA2976634A1 (en) 2016-08-25
IL253873A0 (en) 2017-10-31
RU2017132433A3 (OSRAM) 2019-03-25
EP3259271A2 (en) 2017-12-27
JP2018510139A (ja) 2018-04-12
CA2976634C (en) 2023-10-17
US20170369490A1 (en) 2017-12-28
TW201643161A (zh) 2016-12-16
US20190225609A1 (en) 2019-07-25
KR102647026B1 (ko) 2024-03-12
ES2892954T3 (es) 2022-02-07
KR20170117578A (ko) 2017-10-23
US20160244447A1 (en) 2016-08-25
EP3259271A4 (en) 2018-07-11
EP3925959A1 (en) 2021-12-22
US10301307B2 (en) 2019-05-28
US12286432B2 (en) 2025-04-29
CN114805342A (zh) 2022-07-29
WO2016134223A3 (en) 2016-10-20
RU2017132433A (ru) 2019-03-19
TWI736529B (zh) 2021-08-21
JP2021008511A (ja) 2021-01-28
US20240092775A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
US12286432B2 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
EP2953948B1 (en) Fluorinated integrin antagonists
US10253025B2 (en) Method of making tetrahydronaphthyridinyl nonanoic acid compounds
US10118929B2 (en) Nonanoic and decanoic acid derivatives and uses thereof
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
HK1248677B (en) Fluorinated integrin antagonists
HK1217696B (en) Fluorinated integrin antagonists

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE HAS BEEN EXTENDED TO 12 DEC 2020

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired